Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2024 11:12 ET | Source: InvestorBrandNetwork (IBN)

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
November 06, 2023 07:30 ET | Source: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit

JERUSALEM, Nov. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that the Israel Innovation Authority (IIA) has approved a non-dilutive grant...
November 03, 2023 16:30 ET | Source: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
October 31, 2023 09:00 ET | Source: Scinai Immunotherapeutics Ltd.

European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot

Recently rebranded Scinai Immunotherapeutics shifted drug development focus from COVID-19 antibody to a novel antibody for the treatment of psoriasis and launched a CDMO business unitAdjusted terms...
October 30, 2023 07:00 ET | Source: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023

Showcasing Scinai’s end-to-end cGMP Biologics CDMO services at booth 271 Pursuing partnerships for Scinai’s pipeline of novel VHH antibody-based therapies JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE)...
October 04, 2023 07:30 ET | Source: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023

JERUSALEM, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that it will be showcasing its CDMO services at CPHI Barcelona, one of the...
September 15, 2023 09:01 ET | Source: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering

JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
September 11, 2023 07:30 ET | Source: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston

JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., announced today...
September 06, 2023 06:00 ET | Source: BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to...